Skip to content

Press Releases

You will find all our regulatory press releases in the feed below. Enjoy and share all our other Asarina Pharma news in our regularly updated News Archive.

Asarina Pharma carries out a directed share issue following a request for loan conversion from Östersjöstiftelsen

Solna, 23 June 2022. The Board of Directors of Asarina Pharma AB (publ) (“Asarina Pharma” or the “Company”) has resolved on a directed issue of 3,896,885 shares to Östersjöstiftelsen (ÖSS) following a request for conversion in accordance with convertible loan agreement between Asarina Pharma and ÖSS entered into in May 2021.

Full PDF

Asarina Pharma AB (publ) Q1 2022 Report released

Peter Nordkild, CEO: “Strong, steady progress best sums up Q1 2022. In a productive Quarter we have kept steadfastly to the recruitment goals of our phase IIa Tourette study, despite tail-end Covid-19 effects at our study sites. We firmly expect to continue to do so. The study remains fully funded. We remain confident of reporting…

Full PDF

Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)

The following resolutions were passed at the Annual General Meeting (the “AGM”) of Asarina Pharma AB (publ) (“the Company”) on 4 May 20022.  The Annual General Meeting was carried out through advance voting (postal voting) only.

Full PDF

ASARINA PHARMA AB (publ) ANNUAL REPORT 2021 RELEASED

Peter Nordkild, CEO: “Despite the challenges of the last year we remain committed to our goal of providing new effective therapy to patients with various neurological disorders. Topline data for our phase IIa study in Tourette are still expected in Q1 of 2023 and the study remains fully funded. We maintain our full focus on…

Full PDF

NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (publ)

NOTE: This is an unofficial translation of the original Swedish notice. In case of discrepancies, the Swedish version shall prevail.  The shareholders of Asarina Pharma AB (publ) reg. no. 556698-0750 (the “Company”) are hereby given notice of the Annual General Meeting (the “AGM”) to be held on 4 May 2022.

Full PDF